The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure

International Journal of Cardiology

Volumn 226, Issue , 2017, Pages 121-125

  Rossi, Francesco ^a   Mascolo, Annamaria ^a   Mollace, Vincenzo ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Heart failure; Natriuretic peptides; RAAS NP cross talk; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C;

ADRENERGIC SYSTEM; ARTICLE; CALCIUM HOMEOSTASIS; CARDIAC MUSCLE CELL; HEART ATRIUM REMODELING; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD; HEMODYNAMICS; PHYSIOLOGY;

HEART FAILURE; HEMODYNAMICS; HUMANS; NATRIURETIC PEPTIDES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84962663135     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.080     Document Type: Article

References (52)

1. [1] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14:8 (Aug 2012), 803–869.
2. [2] Roger, V.L., Epidemiology of heart failure. Circ. Res. 113:6 (Aug 30 2013), 646–659.
3. [3] Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 33:14 (Jul 2012), 1750–1757.
4. [4] Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., Butler, J., The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54:19 (Nov 3 2009), 1747–1762.
5. [5] Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, J.A., et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336:16 (Apr 17 1997), 1131–1141.
6. [6] Piacentino, V. 3rd, Weber, C.R., Chen, X., Weisser-Thomas, J., Margulies, K.B., Bers, D.M., et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ. Res. 92:6 (Apr 4 2003), 651–658.
7. [7] Karayannis, G., Kitsios, G., Kotidis, H., Triposkiadis, F., Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. Heart Fail. Rev. 13:1 (Feb 2008), 91–98.
8. [8] Leenen, F.H., Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ. Res. 101:3 (Aug 3 2007), 221–223.
9. [9] Barrese, V., Taglialatela, M., New advances in beta-blocker therapy in heart failure. Front. Physiol., 4, 2013, 323.
10. [10] Mollace, V., Carresi, C., Musolino, V., Maiuolo, J., Oppedisano, F., Gliozzi, M., The effect of beta-2 adrenergic receptor in autophagic response in doxorubicin-induced injury in cardiomiocytes. (in press) Pharmacol. Res., 2015.
11. [11] Bristow, M.R., Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:5 (Feb 8 2000), 558–569.
12. [12] Lymperopoulos, A., Rengo, G., Koch, W.J., Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113:6 (Aug 30 2013), 739–753.
13. [13] Engelhardt, S., Hein, L., Wiesmann, F., Lohse, M.J., Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 96:12 (Jun 8 1999), 7059–7064.
14. [14] Iwase, M., Bishop, S.P., Uechi, M., Vatner, D.E., Shannon, R.P., Kudej, R.K., et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ. Res. 78:4 (Apr 1996), 517–524.
15. [15] Akhter, S.A., Skaer, C.A., Kypson, A.P., McDonald, P.H., Peppel, K.C., Glower, D.D., et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 94:22 (Oct 28 1997), 12100–12105.
16. [16] Rengo, G., Lymperopoulos, A., Leosco, D., Koch, W.J., GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell. Cardiol. 50:5 (May 2011), 785–792.
17. [17] Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A.D., Koch, W.J., Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13:3 (Mar 2007), 315–323.
18. [18] Rockman, H.A., Chien, K.R., Choi, D.J., Iaccarino, G., Hunter, J.J., Ross, J. Jr., et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. U. S. A. 95:12 (Jun 9 1998), 7000–7005.
19. [19] Wong, J., Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab. Vasc. Dis. Res. 10:3 (May 2013), 193–201.
20. [20] Dandan, R., Brunton, L., Chabner, B., Knollman, B., (eds.) Renin and Angiotensin, 2011, McGraw-Hill, New York (NY).
21. [21] Funder, J.W., Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53:2 (Feb 2009), 286–290.
22. [22] Zhou, J., Xu, X., Liu, J.J., Lin, Y.X., Gao, G.D., Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 34:11 (Nov 2007), 1191–1198.
23. [23] Steckelings, U.M., Paulis, L., Namsolleck, P., Unger, T., AT2 receptor agonists: hypertension and beyond. Curr. Opin. Nephrol. Hypertens. 21:2 (Mar 2012), 142–146.
24. [24] Paul, M., Poyan Mehr, A., Kreutz, R., Physiology of local renin-angiotensin systems. Physiol. Rev. 86:3 (Jul 2006), 747–803.
25. [25] Chappell, M.C., Marshall, A.C., Alzayadneh, E.M., Shaltout, H.A., Diz, D.I., Update on the Angiotensin converting enzyme 2-Angiotensin (1–7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front. Endocrinol. (Lausanne), 4(201), 2014.
26. [26] Santos, R.A., Ferreira, A.J., Verano-Braga, T., Bader, M., Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol. 216:2 (Feb 2013), R1–R17.
27. [27] Andersson, H., Hallberg, M., Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int. J. Hypertens., 2012, 2012, 789671.
28. [28] Sanchez-Agesta Ortega, R., de Saavedra-Alias JM, Arias, Liebana-Canada, A., Sanchez-Munoz, B., Martinez-Martos, J.M., Ramirez-Exposito, M.J., Circulating aminopeptidase activities in men and women with essential hypertension. Curr. Med. Chem. 20:38 (2013), 4935–4945.
29. [29] Romero, C.A., Orias, M., Weir, M.R., Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11:4 (Apr 2015), 242–252.
30. [30] Woodard, G.E., Rosado, J.A., Natriuretic peptides in vascular physiology and pathology. Int. Rev. Cell Mol. Biol. 268 (2008), 59–93.
31. [31] de Bold, A.J., Borenstein, H.B., Veress, A.T., Sonnenberg, H., A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1 (Jan 5 1981), 89–94.
32. [32] Sudoh, T., Kangawa, K., Minamino, N., Matsuo, H., A new natriuretic peptide in porcine brain. Nature 332:6159 (Mar 3 1988), 78–81.
33. [33] Sudoh, T., Minamino, N., Kangawa, K., Matsuo, H., C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168:2 (Apr 30 1990), 863–870.
34. [34] Richards, A.M., The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart 76:3 Suppl. 3 (Nov 1996), 36–44.
35. [35] Daniels, L.B., Maisel, A.S., Natriuretic peptides. J. Am. Coll. Cardiol. 50:25 (Dec 18 2007), 2357–2368.
36. [36] Stein, B.C., Levin, R.I., Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am. Heart J. 135:5 Pt 1 (May 1998), 914–923.
37. [37] Maack, T., Suzuki, M., Almeida, F.A., Nussenzveig, D., Scarborough, R.M., McEnroe, G.A., et al. Physiological role of silent receptors of atrial natriuretic factor. Science 238:4827 (Oct 30 1987), 675–678.
38. [38] Potter, L.R., Natriuretic peptide metabolism, clearance and degradation. FEBS J. 278:11 (Jun 2011), 1808–1817.
39. [39] Kerr, M.A., Kenny, A.J., The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J. 137:3 (Mar 1974), 477–488.
40. [40] von Lueder, T.G., Atar, D., Krum, H., Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol. Ther. 144:1 (Oct 2014), 41–49.
41. [41] Deddish, P.A., Marcic, B., Jackman, H.L., Wang, H.Z., Skidgel, R.A., Erdos, E.G., N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1–7) and keto-ACE. Hypertension 31:4 (Apr 1998), 912–917.
42. [42] Pinheiro, S.V., Simoes, E.S.A.C., Angiotensin converting enzyme 2, angiotensin-(1–7), and receptor MAS axis in the kidney. Int. J. Hypertens., 2012, 2012, 414128.
43. [43] Nicholls, M.G., The natriuretic peptides in heart failure. J. Intern. Med. 235:6 (Jun 1994), 515–526.
44. [44] Richards, A.M., Tonolo, G., Tree, M., Robertson, J.I., Montorsi, P., Leckie, B.J., et al. Atrial natriuretic peptides and renin release. Am. J. Med. 84:3A (Mar 11 1988), 112–118.
45. [45] Hunt, P.J., Richards, A.M., Nicholls, M.G., Yandle, T.G., Doughty, R.N., Espiner, E.A., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. 47:3 (Sep 1997), 287–296.
46. [46] McDonagh, T.A., Robb, S.D., Murdoch, D.R., Morton, J.J., Ford, I., Morrison, C.E., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351:9095 (Jan 3 1998), 9–13.
47. [47] Yamamoto, K., Burnett, J.C. Jr., Jougasaki, M., Nishimura, R.A., Bailey, K.R., Saito, Y., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28:6 (Dec 1996), 988–994.
48. [48] Masson, S., Latini, R., Anand, I.S., Vago, T., Angelici, L., Barlera, S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem. 52:8 (Aug 2006), 1528–1538.
49. [49] Mangiafico, S., Costello-Boerrigter, L.C., Andersen, I.A., Cataliotti, A., Burnett, J.C. Jr., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J., 34(12), Mar 2013 (886-93c).
50. [50] Miller, W.L., Phelps, M.A., Wood, C.M., Schellenberger, U., Van Le, A., Perichon, R., et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ. Heart Fail. 4:3 (May 2011), 355–360.
51. [51] Fielitz, J., Dendorfer, A., Pregla, R., Ehler, E., Zurbrugg, H.R., Bartunek, J., et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 105:3 (Jan 22 2002), 286–289.
52. [52] Charloux, A., Piquard, F., Doutreleau, S., Brandenberger, G., Geny, B., Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur. J. Clin. Investig. 33:9 (Sep 2003), 769–778.